NCT03153930

Brief Summary

This study is a randomized crossover trial to compare the effectiveness of interrupting SB on glucose homeostasis in the lab and free-living settings. All participants (N=56) will complete one screening visit to determine eligibility, complete at fitness test, and body composition analysis by bioelectrical impedance. After 7-21 days, all participants will complete two 3-hour in-lab oral glucose tolerance tests (spaced 7-21 days apart). Prior to the in-lab OGTT visits, participants will wear an activity monitor for 7 days on the right thigh. The experimental conditions for the OGTTs will be: 1) 3-hour OGTT of continuous sitting; and 2) 3-hour OGTT with sitting interrupted every 30 minutes with 3-minutes of moderate intensity walking on a treadmill. There will be a 7-21 day washout period between the OGTT visits. In addition, a subset of participants (N=12) who meet inclusion criteria and who successfully complete both OGTT visits will complete a second randomized crossover trial in the free-living environment. The experimental conditions for the free-living components will be: 1) 4 days of habitual sedentary behaviors; and 2) 4 days of prompted short exercise breaks during times in which sedentary behaviors have exceeded 30 minutes. Participants in the free-living trial will wear an activity monitor and a continuous glucose monitor.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 15, 2017

Completed
8 months until next milestone

Study Start

First participant enrolled

January 1, 2018

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2020

Completed
Last Updated

November 13, 2020

Status Verified

November 1, 2020

Enrollment Period

2.4 years

First QC Date

May 12, 2017

Last Update Submit

November 10, 2020

Conditions

Keywords

sedentary behavioryouthmoderating factorsmetabolic outcomes

Outcome Measures

Primary Outcomes (4)

  • In-Lab: Metabolic responses

    glucose, insulin, and c-peptide area under the curve

    3 hours

  • Free-living: Glucose responses

    glucose area under the curve

    4 days

  • Predictors of in-lab glucose responses

    Independent-sample t-tests will assess if mean in-lab glucose AUC differs within experimental condition by weight status (normal weight or overweight/obese). Independent-sample t-tests will assess if mean AUC values between conditions (delta AUC) differ by weight status. Structural equation models of latent growth curves will be used to assess the relationship between BMI z-score trajectories in the preceding 3 years, in-lab glucose AUC responses by experimental condition. Specifically, models will test if a) the higher the initial BMI z score (year 1), the higher the initial serum value (-10 min); b) the higher the initial BMI z score (year 1), the greater the change in serum AUC between experimental conditions; and c) the greater slope of the BMI z score change, the greater the change in serum AUC between experimental conditions.

    3 years

  • Individual variations in glucose responses in-lab

    Mixed-effects location scale models (MIXREGLS) will test how between-subject (BS) and within-subject (WS) variation in SB in the preceding 3 years are associated with glucose responses to in-lab SB interruptions. The predictors are average 3-year SB level and SB level at each year (variation in SB). The Stage 1 mixed-effects location scale model will examine random effects of between-subject variance (i.e., location) and of within-subject variance (i.e., scale), sex, baseline percent body fat, and baseline age. The Stage 2 model will assess how these variance sources from Stage 1 affect the delta AUC between in-lab prolonged SB and SB interruptions with regards to glucose (the WS effects).

    3 years

Secondary Outcomes (1)

  • Relationship between in-lab and free-living glucose AUC

    5 days

Study Arms (2)

Sitting Only (SIT)

PLACEBO COMPARATOR

In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor

Behavioral: Sitting only

Walking Breaks (WALK)

EXPERIMENTAL

In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor

Behavioral: Walking breaks

Interventions

Walking breaksBEHAVIORAL

In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes

Also known as: Interrupting sedentary time
Walking Breaks (WALK)
Sitting onlyBEHAVIORAL

In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors

Also known as: Continuous sedentary time
Sitting Only (SIT)

Eligibility Criteria

Age11 Years - 16 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • current/past participant in the MATCH Study
  • good general health
  • fasting plasma glucose \<100 mg/dL
  • BMI greater than the 5th percentile

You may not qualify if:

  • significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion
  • evidence of impaired glucose tolerance or type 2 diabetes
  • presence of other endocrinologic disorders leading to obesity (e.g.: Cushing Syndrome)
  • current or past anti-psychotic drugs use that would affect metabolism
  • non-diet treatment for hypertension or dyslipidemia
  • precocious puberty and/or receiving androgen and estrogen therapy
  • medication use known to affect body composition/weight

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Southern California Keck School of Medicine

Los Angeles, California, 90032, United States

Location

MeSH Terms

Conditions

Sedentary BehaviorPediatric ObesityMotor Activity

Condition Hierarchy (Ancestors)

BehaviorObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Britni R Belcher, PhD, MPH

    University of Southern California

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Participants will complete a randomized crossover study with 2 conditions: sitting continuously for 3 hours vs. interrupting sitting with 3-minute moderate intensity walking breaks every 30 minutes for 3 hours. A subset will then complete a free-living component wearing a continuous glucose monitor that will consist of habitual activity vs. interrupting periods of 30+ sedentary minutes with short activity breaks.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Preventive Medicine

Study Record Dates

First Submitted

May 12, 2017

First Posted

May 15, 2017

Study Start

January 1, 2018

Primary Completion

June 1, 2020

Study Completion

June 30, 2020

Last Updated

November 13, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

We do not intend to share IPD with other researchers outside of our study.

Locations